ArticleBlood2015
β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome.
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 73 citations in OpenAlex.
- Immune-induced TCR-like antibodies regulate specific T cell response in mice.Nature communications · 2026Article
- Anti-β2GPI/HLA-DR Antibody, Chronic Endometritis, and Uterine Endometrial Microbiome in Women with Recurrent Pregnancy Loss: A Prospective Cohort Study.Microorganisms · 2026Article
- Article
- Antiphospholipid Syndrome: An Antibody-Mediated Disease With Emerging Therapeutic Opportunities.Arthritis & rheumatology (Hoboken, N.J.) · 2025Review
- B Cell Tolerance and Obstetric Antiphospholipid Syndrome.Clinical reviews in allergy & immunology · 2025Review
- Article
- Coronary microvascular dysfunction: a review of its association with extracardiac organ pathologies.Frontiers in cardiovascular medicine · 2025Review
- Pregnancy outcomes in women with anti-β2-glycoprotein I/human leukocyte antigen-DR autoantibodies receiving assisted reproductive technology: a prospective cohort study.Frontiers in immunology · 2025Observational
- Immune-mediated mechanisms and maternal-fetal interface dysfunction in obstetric antiphospholipid syndrome.Frontiers in immunology · 2025Review
- The well-defined antiphospholipid syndrome induced by COVID-19: a rare case report and review of the literature.Thrombosis journal · 2024Review
- Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults.Journal of clinical medicine · 2024Review
- Neoself Antigens Presented on MHC Class II Molecules in Autoimmune Diseases.Advances in experimental medicine and biology · 2024Article
- Low-dose aspirin and heparin treatment improves pregnancy outcome in recurrent pregnancy loss women with anti-β2-glycoprotein I/HLA-DR autoantibodies: a prospective, multicenter, observational study.Frontiers in immunology · 2024Observational
- Article
- Association of anti-β2-glycoprotein I/HLA-DR complex antibody with arterial thrombosis in female patients with systemic rheumatic diseases.Arthritis research & therapy · 2023Article
- The pathogenesis of obstetric APS: a 2023 update.Clinical immunology (Orlando, Fla.) · 2023Review
- Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes.International journal of molecular sciences · 2023Article
- Abrogation of self-tolerance by misfolded self-antigens complexed with MHC class II molecules.Science advances · 2022Article
- Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome.Frontiers in cardiovascular medicine · 2022Review
- Are DNA-HLA class II interactions the missing link in SLE?Nature reviews. Rheumatology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 8 institutions in 2 countries.
Funding
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and/or pregnancy complications. β2-glycoprotein I (β2GPI) complexed with phospholipid is recognized as a major target for autoantibodies in APS; however, less than half the patients with clinical manifestations of APS possess autoantibodies against the complexes. Therefore, the range of autoantigens involved in APS remains unclear. Recently, we found that human leukocyte antigen (HLA) class II molecules transport misfolded cellular proteins to the cell surface via association with their peptide-binding grooves. Furthermore, immunoglobulin G heavy chain/HLA class II complexes were specific targets for autoantibodies in rheumatoid arthritis. Here, we demonstrate that intact β2GPI, not peptide, forms a complex with HLA class II molecules. Strikingly, 100 (83.3%) of the 120 APS patients analyzed, including those whose antiphospholipid antibody titers were within normal range, possessed autoantibodies that recognize β2GPI/HLA class II complexes in the absence of phospholipids. In situ association between β2GPI and HLA class II was observed in placental tissues of APS patients but not in healthy controls. Furthermore, autoantibodies against β2GPI/HLA class II complexes mediated complement-dependent cytotoxicity against cells expressing the complexes. These data suggest that β2GPI/HLA class II complexes are a target in APS that might be involved in the pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.